BioMarin Pharmaceutical (NASDAQ:BMRN) Receives New Coverage From Analysts at BMO Capital Markets
BioMarin Pharmaceutical (NASDAQ:BMRN) Receives New Coverage From Analysts at BMO Capital Markets
BMO Capital Markets initiated coverage on shares of BioMarin Pharmaceutical (NASDAQ:BMRN – Get Rating) in a research report released on Monday morning, The Fly reports. The brokerage issued a market perform rating and a $107.00 price target on the biotechnology company's stock.
据The Fly报道,蒙特利尔银行资本市场在周一上午发布的一份研究报告中首次对BioMarin制药公司(BMRN-GET评级)的股票进行了报道。该经纪公司对这家生物技术公司的股票发布了市场表现评级和107.00美元的目标价。
BMRN has been the topic of several other reports. StockNews.com assumed coverage on BioMarin Pharmaceutical in a report on Wednesday, October 12th. They set a buy rating on the stock. Morgan Stanley raised their price target on shares of BioMarin Pharmaceutical from $113.00 to $132.00 and gave the company an overweight rating in a report on Tuesday, January 24th. Evercore ISI boosted their price objective on shares of BioMarin Pharmaceutical to $130.00 in a report on Friday, December 2nd. Guggenheim raised their target price on BioMarin Pharmaceutical from $120.00 to $125.00 in a research note on Monday, January 9th. Finally, Canaccord Genuity Group began coverage on BioMarin Pharmaceutical in a research report on Wednesday, January 18th. They set a hold rating and a $119.00 target price on the stock. Four equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of Moderate Buy and a consensus target price of $119.39.
BMRN一直是其他几份报告的主题。斯托克新闻网在10月12日星期三的一份报告中对BioMarin制药公司进行了报道。他们对这只股票设定了买入评级。摩根士丹利在1月24日(周二)的一份报告中将他们对BioMarin Pharmtics的股票目标价从113.00美元上调至132.00美元,并给予该公司增持评级。在12月2日星期五的一份报告中,Evercore ISI将他们对BioMarin制药公司的股票目标价上调至130.00美元。1月9日,古根海姆在一份研究报告中将他们对BioMarin制药公司的目标价从120.00美元上调至125.00美元。最后,Canaccel Genuity集团在1月18日星期三的一份研究报告中开始报道BioMarin制药公司。他们为该股设定了持有评级和119.00美元的目标价。4名股票研究分析师对该股的评级为持有,12名分析师对该股的评级为买入。根据MarketBeat的数据,该股目前的平均评级为适度买入,共识目标价为119.39美元。
BioMarin Pharmaceutical Stock Down 2.2 %
BioMarin制药类股下跌2.2%
Shares of BioMarin Pharmaceutical stock opened at $114.70 on Monday. BioMarin Pharmaceutical has a twelve month low of $70.73 and a twelve month high of $117.77. The stock has a market cap of $21.27 billion, a price-to-earnings ratio of 274.00 and a beta of 0.36. The company has a current ratio of 5.15, a quick ratio of 3.54 and a debt-to-equity ratio of 0.24. The company has a fifty day moving average price of $105.75 and a 200 day moving average price of $94.50.
周一,BioMarin制药公司的股票开盘报114.70美元。BioMarin制药的12个月低点为70.73美元,12个月高位为117.77美元。该股市值为212.7亿美元,市盈率为274.00,贝塔系数为0.36.该公司的流动比率为5.15,速动比率为3.54,债务权益比率为0.24。该公司的50日移动平均价为105.75美元,200日移动平均价为94.5美元。
Insider Activity
内幕活动
Institutional Investors Weigh In On BioMarin Pharmaceutical
机构投资者看好BioMarin制药公司
Hedge funds have recently made changes to their positions in the business. Altshuler Shaham Ltd bought a new stake in shares of BioMarin Pharmaceutical during the third quarter valued at about $25,000. Quadrant Capital Group LLC raised its position in shares of BioMarin Pharmaceutical by 188.6% during the 2nd quarter. Quadrant Capital Group LLC now owns 355 shares of the biotechnology company's stock worth $29,000 after buying an additional 232 shares in the last quarter. Acadian Asset Management LLC lifted its stake in shares of BioMarin Pharmaceutical by 395.4% in the 1st quarter. Acadian Asset Management LLC now owns 431 shares of the biotechnology company's stock worth $32,000 after acquiring an additional 344 shares during the period. Capital Wealth Alliance LLC bought a new position in shares of BioMarin Pharmaceutical in the second quarter valued at approximately $34,000. Finally, Baystate Wealth Management LLC acquired a new position in shares of BioMarin Pharmaceutical during the fourth quarter valued at approximately $41,000. Institutional investors own 96.26% of the company's stock.
对冲基金最近对其在该业务中的头寸进行了调整。Altshuler Shaham Ltd在第三季度购买了BioMarin制药公司的新股份,价值约2.5万美元。跨骏资本集团在第二季度将其在BioMarin制药公司的股票头寸增加了188.6%。跨骏资本集团现在持有这家生物技术公司355股股票,价值2.9万美元,上个季度又购买了232股。Acadian Asset Management LLC在第一季度增持了BioMarin制药公司的股份395.4%。Acadian Asset Management LLC在此期间额外收购了344股,现在拥有431股这家生物技术公司的股票,价值3.2万美元。资本财富联盟有限责任公司在第二季度购买了BioMarin制药公司的新股票,价值约3.4万美元。最后,BayState Wealth Management LLC在第四季度收购了BioMarin制药公司的新股票,价值约为4.1万美元。机构投资者持有该公司96.26%的股票。
About BioMarin Pharmaceutical
关于BioMarin制药公司
(Get Rating)
(获取评级)
BioMarin Pharmaceutical, Inc engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M.
BioMarin制药公司致力于为患有严重和危及生命的罕见疾病和医疗条件的人开发治疗方法并将其商业化。它的流水线产品包括Valoctocogene roxparvovec、vosoritie和BMN 307。该公司由约翰·C·克洛克、克里斯托弗·M。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on BioMarin Pharmaceutical (BMRN)
- Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
- SoFi Technologies Smashes Earnings but Beware the Fed Decision
- Buying The Dip In Colgate-Palmolive
- Mullen Automotive On Hiring Spree, What Could That Mean?
- InterDigital Raises Its Earnings Guidance
- 免费获取StockNews.com关于BioMarin制药公司(BMRN)的研究报告
- 为什么黄金现在可以成为你投资组合中的闪闪发光的一部分
- 索菲技术公司盈利惨淡,但要警惕美联储的决定
- 购买高露洁棕榄中的Dip
- 马伦汽车(Mullen Automotive)大举招聘,这可能意味着什么?
- InterDigital上调盈利指引
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
获得《BioMarin药学日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对BioMarin制药公司和相关公司的最新新闻和分析师评级的每日简要摘要。